Legacy Wealth Asset Management LLC Acquires 12,692 Shares of Danaher Corporation $DHR

Legacy Wealth Asset Management LLC bought a new position in Danaher Corporation (NYSE:DHR) during the third quarter, Holdings Channel reports. The fund bought 12,692 shares of the conglomerate’s stock, valued at approximately $2,812,000.

Other large investors also recently bought and sold shares of the company. Chapin Davis Inc. bought a new position in Danaher during the 3rd quarter valued at approximately $957,000. Hardin Capital Partners LLC purchased a new stake in Danaher during the 3rd quarter valued at about $626,000. Pacifica Partners Inc. bought a new position in shares of Danaher in the third quarter worth approximately $239,000. Stableford Capital II LLC grew its holdings in shares of Danaher by 292.4% during the third quarter. Stableford Capital II LLC now owns 18,766 shares of the conglomerate’s stock valued at $4,158,000 after buying an additional 13,984 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its holdings in Danaher by 1.2% in the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 188,136 shares of the conglomerate’s stock worth $41,682,000 after acquiring an additional 2,200 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DHR. Evercore reaffirmed an “outperform” rating and set a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Guggenheim lifted their target price on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. The Goldman Sachs Group lifted their price target on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Piper Sandler assumed coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target on the stock. Finally, Royal Bank Of Canada boosted their target price on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $235.23.

Danaher Stock Down 0.5%

Shares of DHR stock opened at $217.33 on Friday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The stock’s fifty day moving average price is $210.88 and its 200 day moving average price is $194.44. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market cap of $152.78 billion, a price-to-earnings ratio of 38.60, a price-to-earnings-growth ratio of 2.72 and a beta of 0.76.

Danaher (NYSE:DHR) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.77 EPS. On average, research analysts expect that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.